JENTADUETO®: Powerful HbA1c reductions for high baseline metformin-uncontrolled patients1.


Placebo-adjusted mean HbA1c change from baseline at 24 weeks*

JENTADUETO®: Powerful HbA1c reductions for high baseline metformin-uncontrolled patients

*24-week, double-blind, placebo-controlled, Phase III trial. Two arms received linagliptin 2.5 mg twice daily (BID) + either low (500 mg) or high (1,000 mg) dose metformin BID. Four arms received linagliptin 5 mg once daily, metformin 500 mg or 1,000 mg BID or placebo. Patients with HbA1c ≥11.0% were not eligible for randomisation and received open-label linagliptin + high-dose metformin. High baseline defined as HbA1c >8.5% to <11.0%.

BID: Twice daily.

Hear what experts are saying about the convenience of JENTADUETO®